KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Non Operating Income (2019 - 2025)

Royalty Pharma's Non Operating Income history spans 7 years, with the latest figure at -$229.1 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 204.01% year-over-year to -$229.1 million; the TTM value through Dec 2025 reached -$235.3 million, down 15300.92%, while the annual FY2025 figure was -$235.3 million, 15300.92% down from the prior year.
  • Non Operating Income for Q4 2025 was -$229.1 million at Royalty Pharma, down from -$1.6 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $211.4 million in Q4 2023 and bottomed at -$229.1 million in Q4 2025.
  • The 5-year median for Non Operating Income is $2.6 million (2021), against an average of $3.9 million.
  • The largest YoY upside for Non Operating Income was 23580.46% in 2021 against a maximum downside of 1087.2% in 2021.
  • A 5-year view of Non Operating Income shows it stood at $84.1 million in 2021, then plummeted by 251.47% to -$127.4 million in 2022, then skyrocketed by 265.94% to $211.4 million in 2023, then crashed by 135.66% to -$75.4 million in 2024, then crashed by 204.01% to -$229.1 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Non Operating Income are -$229.1 million (Q4 2025), -$1.6 million (Q3 2025), and $96.1 million (Q2 2025).